查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1411695

糖尿病肾臟病变治疗市场：按治疗类型、最终用户划分 - 全球预测 2024-2030

Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年糖尿病肾臟病变治疗市场规模为22.6亿美元，预计2024年将达23.8亿美元，2030年将达32.8亿美元，复合年增长率为5.46%。

糖尿病肾臟病变治疗的全球市场

主要市场统计
基准年[2023] 22.6亿美元
预测年份 [2024] 23.8亿美元
预测年份 [2030] 32.8亿美元
复合年增长率（%） 5.46%
糖尿病肾病变治疗市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估糖尿病肾臟病变治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对糖尿病肾臟病变治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-糖尿病肾臟病变治疗市场的市场规模与预测是多少？

2-糖尿病肾臟病变治疗市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-糖尿病肾臟病变治疗市场的技术趋势和法律规范是什么？

4-糖尿病肾臟病变治疗市场主要供应商的市场占有率是多少？

5-进入糖尿病肾臟病变治疗市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着老年人口的增加，全球糖尿病盛行率正在上升
      • 政府主导努力解决糖尿病及其併发症的负担
      • 更重视以病人为中心的糖尿病肾臟病护理计划
    • 抑制因素
      • 糖尿病肾臟病变治疗费用高
    • 机会
      • 介绍一种新的、更有效的糖尿病肾臟病治疗方法
      • 改善糖尿病肾臟病变治疗的报销政策和医疗保健
    • 任务
      • 与糖尿病肾臟病变相关的合併症和护理复杂性
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章依治疗类型分類的糖尿病肾臟病变治疗市场

  • 末期肾病（ESRD）的治疗
    • 肾臟透析
    • 移植
  • 药品
    • 血管收缩素2 受体阻断剂(ARB)
    • 血管收缩素转化酵素(ACE) 抑制剂
    • 降低胆固醇药物
    • 二甲双胍
  • 药物治疗

第七章 糖尿病肾臟病变治疗市场：依最终使用者分类

  • 医院
  • 肾臟内科门诊

第八章北美及南美糖尿病肾臟病变治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区糖尿病肾臟病变治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲糖尿病肾臟病变治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：按主要企业划分
  • 主要企业竞争情境分析

第12章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma Limited
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • ChemoCentryx, Inc.
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Endo International PLC
    • IQVIA Inc.
    • Johnson & Johnson Services, Inc.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc.
    • Mesoblast Ltd
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Reata Pharmaceuticals, Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-2A0283E256D1

[198 Pages Report] The Diabetic Nephropathy Treatment Market size was estimated at USD 2.26 billion in 2023 and expected to reach USD 2.38 billion in 2024, at a CAGR 5.46% to reach USD 3.28 billion by 2030.

Global Diabetic Nephropathy Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.26 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.28 billion
CAGR (%) 5.46%
Diabetic Nephropathy Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Nephropathy Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Nephropathy Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Nephropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, ChemoCentryx, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International PLC, IQVIA Inc., Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mesoblast Ltd, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Reata Pharmaceuticals, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Diabetic Nephropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • End-stage Renal Disease (ESRD) Treatment
      • Kidney Dialysis
      • Transplant
    • Medications
      • Angiotensin 2 Receptor Blockers (ARBs)
      • Angiotensin-converting Enzyme (ACE) Inhibitors
      • Cholesterol-lowering Drugs
      • Metformin
    • Pharmacological Treatment
  • End-User
    • Hospitals
    • Nephrology Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Nephropathy Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Nephropathy Treatment Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Nephropathy Treatment Market?

4. What is the market share of the leading vendors in the Diabetic Nephropathy Treatment Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Nephropathy Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Diabetic Nephropathy Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Government-led initiatives to address the burden of diabetes and its complications
      • 5.1.1.3. Growing emphasis on patient-centric care plans for diabetic nephropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetic nephropathy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and more effective diabetic nephropathy treatments
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities and complexity of care associated with diabetic nephropathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Diabetic Nephropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. End-stage Renal Disease (ESRD) Treatment
    • 6.3.1. Kidney Dialysis
    • 6.3.2. Transplant
  • 6.3. Medications
    • 6.4.1. Angiotensin 2 Receptor Blockers (ARBs)
    • 6.4.2. Angiotensin-converting Enzyme (ACE) Inhibitors
    • 6.4.3. Cholesterol-lowering Drugs
    • 6.4.4. Metformin
  • 6.4. Pharmacological Treatment

7. Diabetic Nephropathy Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Nephrology Clinics

8. Americas Diabetic Nephropathy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Nephropathy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Nephropathy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. AbbVie Inc.
    • 12.1.3. Amgen Inc.
    • 12.1.4. AstraZeneca PLC
    • 12.1.5. Aurobindo Pharma Limited
    • 12.1.6. Bayer AG
    • 12.1.7. Boehringer Ingelheim International GmbH
    • 12.1.8. Bristol-Myers Squibb Company
    • 12.1.9. ChemoCentryx, Inc.
    • 12.1.10. Daiichi Sankyo Company, Limited
    • 12.1.11. Dr. Reddy's Laboratories Ltd.
    • 12.1.12. Eli Lilly and Company
    • 12.1.13. Endo International PLC
    • 12.1.14. IQVIA Inc.
    • 12.1.15. Johnson & Johnson Services, Inc.
    • 12.1.16. Mallinckrodt Pharmaceuticals
    • 12.1.17. Merck & Co., Inc.
    • 12.1.18. Mesoblast Ltd
    • 12.1.19. Novartis AG
    • 12.1.20. Otsuka Pharmaceutical Co., Ltd.
    • 12.1.21. Pfizer, Inc.
    • 12.1.22. Reata Pharmaceuticals, Inc.
    • 12.1.23. Sanofi SA
    • 12.1.24. Sun Pharmaceutical Industries Ltd.
    • 12.1.25. Teva Pharmaceutical Industries Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DIABETIC NEPHROPATHY TREATMENT MARKET DYNAMICS
  • FIGURE 7. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY KIDNEY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 12. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN 2 RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. DIABETIC NEPHROPATHY TREATMENT MARKET LICENSE & PRICING